| NCT ID | NCT07433010 |
| Status | Recruiting |
| Phase | — |
| Sponsor | RWTH Aachen University |
| Condition | Dementia Disorder |
| Study Type | OBSERVATIONAL |
| Enrollment | 5,000 participants |
| Start Date | 2022-05-16 |
| Primary Completion | 2099-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 5,000 participants in total. It began in 2022-05-16 with a primary completion date of 2099-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The German Dementia Registry (DEMREG) is a large-scale national prospective biomarker-based study for cognitive impairment and dementia, providing an integrated clinical research platform for research studies.
Eligibility Criteria
Inclusion Criteria: Inclusion Criteria for Patient: * Ability of the participant and/or his/her legally authorized representative (e.g., spouse or legal guardian), as appropriate and applicable, to understand the purpose and risks of the register and provide signed and dated informed consent and authorization to use protected health information (PHI) in accordance with national and local privacy regulations. * Participating patients must have a diagnosis of SCD, MCI or early dementia of different etiology (i.e. Alzheimer's Disease, Frontotemporal Dementia, Parkinson's Disease, Lewy-Body Dementia, Progressive Supranuclear Palsy, Corticobasal Degeneration, Normal Pressure Hydrocephalus, Major Depression; Vascular Dementia; TDP-43 associated limbic encephalopathy (LATE), Mixed Dementia AD + VaD, Prion-Associated Dementia) together with biomarkers such as cerebrospinal fluids (CSF) amyloid beta 1-42, amyloid beta 1-40, amyloid beta 1-42/amyloid beta 1-40 ratio, total tau and phosphorylated tau, amyloid or tau imaging. * At least 18 years of age. Inclusion Criteria for family member: * At least 18 years of age. * Patient was included in the registry * Family member is strongly involved to the patient's life according to the patient's statement * Ability of the participant, as appropriate and applicable, to understand the purpose and risks of the register Exclusion Criteria: Exclusion Criteria for Patient: * Unwilling to provide informed consent. * No available biomarkers such as cerebrospinal fluids (CSF) amyloid beta 1-42, amyloid beta 1-40, amyloid beta 1-42/amyloid beta 1-40 ratio, total tau and phosphorylated tau, amyloid or tau imaging. Exclusion Criteria for family member: * Unable or unwilling to provide informed consent.
Contact & Investigator
Jörg B. Schulz, Prof. Dr.
PRINCIPAL INVESTIGATOR
Department of Neurology, RWTH Aachen University Hospital
Frequently Asked Questions
Who can join the NCT07433010 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Dementia Disorder. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07433010 currently recruiting?
Yes, NCT07433010 is actively recruiting participants. Contact the research team at NE-Wissenschaftsmanagement@ukaachen.de for enrollment information.
Where is the NCT07433010 trial being conducted?
This trial is being conducted at Heidelberg, Germany, Mannheim, Germany, Tübingen, Germany, Ulm, Germany and 11 additional locations.
Who is sponsoring the NCT07433010 clinical trial?
NCT07433010 is sponsored by RWTH Aachen University. The principal investigator is Jörg B. Schulz, Prof. Dr. at Department of Neurology, RWTH Aachen University Hospital. The trial plans to enroll 5,000 participants.